Neurocrine Biosciences

World Rank (Jul-30-2023)
1,672
Market Cap (Jul-30-2023)
10.026 Billion USD
World Rank (Dec-25-2022)
1,362
Market Cap (Dec-25-2022)
11.566 Billion USD
World Rank (Jan-07-2022)
2,475
Market Cap (Jan-07-2022)
7.145 Billion USD
World Rank (Jan-01-2021)
1,837
Market Cap (Jan-01-2021)
8.955 Billion USD
Company Rank in Country in 2023
Company Rank in USA in July-2023 is 628
Annual Revenue in USD
1,488 Million USD
Annual Net Income in USD
154 Million USD
Total Assets in USD
2,368 Million USD
Total Liabilities in USD
660 Million USD
Annual Results for Year ending in
Dec-2022 month
Headquarters State / City
California
Headquarters Country
USA
Company Business
Healthcare
Pharmaceutical
Biopharmaceutical
Biotechnology
Technology
Stock Exchange
Nasdaq
Company Rank in Country in 2022
Company Rank in USA in 2022 is 875
Rank in Country (Jan-2021)
Company Rank in USA in 2021 is 656
Rank in Country (Jan-2020)
Rank in USA in 2020 is 555
Number of Employees
1,200
Employee Count as on Date
As on 2022
Yahoo
Yahoo @ Nasdaq
Wikipedia
Wikipedia
Company Website:
NEUROCRINE BIOSCIENCES INC
About Company Business:

Neurocrine Biosciences is a Neuroscience Focused and Biopharmaceutical company. It is discovering and developing life-changing treatments for people with serious, challenging, under addressed neurological, endocrine and psychiatric disorders. The headquarters is in USA. 

IPO Year
1996
Founded Year
1992
Annual Results Summary:

NEUROCRINE BIOSCIENCES - Annual Results Summary - in Million USD

Year Ending: Total Revenue Net Income
Dec-2022 1,488 154
Dec-2021 1,135 89
Dec-2020 80,303 3,301
Dec-2019 103,915 19,549
Dec-2018 101,060 22,393
Dec-2017 97,741 22,183
Balance Sheet Summary

Total Assets as on Dec-2022 was 2,368 Million USD.

Total Liabilities as on Dec-2022 was 660 Million USD.

Total Equity as on Dec-2022 was 1,707 Million USD.

Share it on Social Media